All In Biotech

Drug Trial Radar · NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Conditions

  • Metastatic Solid Tumor
  • Recurrent Solid Tumor
  • Advanced Solid Tumor
  • Urinary Bladder Neoplasm
  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Esophageal Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Prostate Cancer
  • Renal Pelvis Cancer
  • Bladder Cancer

Interventions

  • LY4052031Drug

    Intravenous

  • PembrolizumabDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031Time frame: Cycle 1 (21 Days)
  2. Phase 1b: To assess the antitumor activity of LY4052031 as monotherapy or in combination with pembrolizumab: Overall response rate (ORR)Time frame: Up to Approximately 48 Months or 4 Years

Locations

40 sites in 8 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • University of California, San Diego (UCSD) - Moores Cancer Center

    La Jolla, California · Recruiting

  • UCLA Department of Medicine-Hematology/Oncology

    Los Angeles, California · Recruiting

  • Sarah Cannon Research Institute at HealthOne

    Denver, Colorado · Recruiting

  • Florida Cancer Specialists and Research Institute

    St. Petersburg, Florida · Completed

  • Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Hospital

    Chicago, Illinois · Recruiting

  • IU Simon Cancer Center

    Indianapolis, Indiana · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • START Midwest Cancer and Hematology Centers of W Michigan

    Grand Rapids, Michigan · Recruiting

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri · Recruiting

  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)

    New York, New York · Recruiting

  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)

    New York, New York · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology PLLC

    Nashville, Tennessee · Not yet recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas · Recruiting

  • University of Utah - Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • St Vincent's Hospital

    Darlinghurst, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Australia · Recruiting

  • Beijing Cancer hospital

    Beijing, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China · Recruiting

  • Institut Gustave Roussy (Igr)

    Villejuif, France · Recruiting

  • National Cancer Center Hospital

    Chūōku, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • The Cancer Institute Hospital of JFCR

    Kōtō City, Japan · Recruiting

  • Aichi Cancer Center Hospital

    Nagoya, Japan · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Catalan Institute of Oncology Duran i Reynals Hospital

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Madrid Norte Sanchinarro

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen Del Rocio

    Seville, Spain · Recruiting

  • St Bartholomew's Hospital

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.